Single Patient Expanded Access Protocol: Metabolic Boost (14070 Boost)

Expanded access is no longer available for this treatment.
Sponsor:
Collaborator:
Duke University
Information provided by (Responsible Party):
University of Louisville
ClinicalTrials.gov Identifier:
NCT02021266
First received: December 19, 2013
Last updated: April 21, 2014
Last verified: April 2014
  Purpose

This is a single patient expanded access protocol to investigate the effects of a second dose of facilitating cell-enhanced hematopoietic stem cell product.


Condition Intervention
Metachromatic Leukodystrophy
Biological: Enriched Hematopoetic Stem Cell Transplant

Study Type: Expanded Access     What is Expanded Access?
Official Title: Single Patient Expanded Access Protocol: Phase I/II Pilot Study of Mixed Chimerism to Treat Inherited Metabolic Disorders

Resource links provided by NLM:


Further study details as provided by University of Louisville:

Intervention Details:
    Biological: Enriched Hematopoetic Stem Cell Transplant
    Bone marrow will be processed via a new technology which will enrich hematopoietic stem cells and graft facilitating cells. Monitoring for chimerism will be done at key time points.
Detailed Description:

Hematopoietic stem cell transplantation (HSCT) has been established as an important therapeutic option for patients with a variety of inherited metabolic disorders (IMD). The potential life-threatening complications of conventional myeloablative HSCT have limited its application. Additionally, conventional HSCT is only available to the small minority of medically suitable candidates who have histocompatibility leukocyte antigen (HLA)-identical siblings to donate bone marrow or mobilized peripheral blood stem cells.

Donor mobilized peripheral blood stem cells or bone marrow will be processed via a novel technology to deplete mature immune cells while retaining hematopoietic stem cells (HSC) and graft facilitating cells (FC).

A now-standard reduced intensity, nonmyeloablative recipient conditioning regimen will be used to promote mixed allogeneic chimerism, thereby significantly reducing morbidity and mortality.

These two enhancements are intended to significantly improve the benefit:risk ratio of HSCT for patients with IMDs. If successful, transplantation will become a more feasible option for patients without HLA-identical siblings to donate stem cells, and could be offered to patients early in disease progression.

The objective for the study is to establish chimerism following reduced intensity conditioning with no grade III/IV graft-versus-host disease (GVHD). The primary endpoint we will follow is production of the missing enzyme at ≥ 10% of the normal level at day 180 post-transplant as for investigational new drug (IND) 14070. This expanded access protocol details the approach to providing a second dose of the product.

  Eligibility

Genders Eligible for Study:   Female
Criteria

Inclusion Criteria:

Subject was previously enrolled and qualified for transplant under IND 14070. Subject must be free from infection and have normal liver, kidney, heart and pulmonary function to proceed to a second transplant.

  1. Patient must have adequate function of other organ systems as measured by:

    • Creatinine < 2.0 mg/dl and creatinine clearance ≥60 cc/min/1.73m2. Newborns must have a creatinine clearance > 25 cc/min. For babies < 3 months of age, the raw value on GFR must be > 1 cc/kg/min.
    • Hepatic transaminases (ALT/AST) 2.5 x normal, bilirubin <2.0mg/dl
    • Normal cardiac function by echocardiogram or radionuclide scan (ejection fraction or shortening fraction >80% of normal value for age)
    • Pulmonary function tests (PFT) demonstrating forced expiratory volume at one second (FEV1) of >50% of predicted for age. If child is too young or unable to perform PFTs, crying vital capacity result of >50% of normal value for age or resting pulse oximeter >92% on room air or clearance by pulmonologist will be required.
  2. Patient, and parent, or legal guardian must have given written informed consent according to FDA guidelines.
  3. Patient must have a minimum life expectancy of at least 6 months.
  4. Female patients of childbearing potential cannot be pregnant or lactating/breast-feeding and must be either surgically sterile, postmenopausal (no menses for the previous 12 months), or must be practicing an effective method of birth control as determined by the investigator (e.g., oral contraceptives, double barrier methods, hormonal injectable or implanted contraceptives, tubal ligation, or partner with vasectomy).
  5. Recipient screening to include glomerular filtration rate (GFR), chest X-ray (CXR), hepatic and renal chemistries, coagulation studies, pulmonary function testing, and ECHO if clinically relevant, chimerism testing, type and screen, and enzyme levels within 30 days of retransplant.

Exclusion Criteria:

  1. Uncontrolled seizures, apnea, evidence of recurrent or uncontrolled aspiration, or need for chronic mechanical ventilation.
  2. Subject must not have had previous radiation therapy that would preclude total body irradiation (TBI) (as determined by radiation therapist)
  3. Uncontrolled infection or severe concomitant diseases, which in the judgment of the Principal Investigator, could not tolerate reduced intensity transplantation.
  4. Subject with a positive human immunodeficiency virus (HIV) antibody test result
  5. Subject who are pregnant, as indicated by a positive serum human chorionic gonadotropin (HCG) test
  6. Subject whose only donor is pregnant at the time of intended transplant
  7. Subject of childbearing potential who are not practicing adequate contraception as defined by the investigator at the site
  8. Jehovah's witnesses being unwilling to be transfused
  9. Patient that have any comorbid condition which, in the view of the Principal Investigators, renders the patient at too high a risk from treatment complications and regimen related morbidity/mortality.
  10. Insufficient funds for bone marrow processing.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02021266

Locations
United States, North Carolina
Duke University
Durham, North Carolina, United States, 27705
Sponsors and Collaborators
University of Louisville
Duke University
Investigators
Principal Investigator: Joanne Kurtzberg, MD Duke University
  More Information

No publications provided

Responsible Party: University of Louisville
ClinicalTrials.gov Identifier: NCT02021266     History of Changes
Other Study ID Numbers: ICT-14070-120611-Exp Access
Study First Received: December 19, 2013
Last Updated: April 21, 2014
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Leukodystrophy, Metachromatic
Hereditary Central Nervous System Demyelinating Diseases
Brain Diseases, Metabolic, Inborn
Brain Diseases, Metabolic
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Sulfatidosis
Sphingolipidoses
Lysosomal Storage Diseases, Nervous System
Leukoencephalopathies
Demyelinating Diseases
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Lipidoses
Lipid Metabolism, Inborn Errors
Lysosomal Storage Diseases
Metabolic Diseases
Lipid Metabolism Disorders

ClinicalTrials.gov processed this record on August 20, 2014